Immunovant

New York, United States

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.

$550.0M raised

Dec 2025

Post-IPO Equity

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Immunovant raised?

Immunovant has raised $550.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2025.

Who are Immunovant's investors?

Immunovant's investors include TCG Crossover, Frazier Life Sciences, Frazier Healthcare Partners, Roivant Sciences, Commodore Capital.

Where is Immunovant headquartered?

Immunovant is headquartered in New York, United States.

What does Immunovant do?

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.

What stage is Immunovant at?

Immunovant is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated December 11, 2025.

MLA

"Immunovant — Funding & Investors." VCBacked, December 11, 2025, https://www.vcbacked.co/company/immunovant. Accessed July 2, 2026.

APA

VCBacked. (2025). Immunovant — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/immunovant

Wikipedia (cite web)

{{cite web |title=Immunovant — Funding & Investors |url=https://www.vcbacked.co/company/immunovant |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated December 11, 2025.